Paris, France et Camberley, Royaume-Uni – 2 novembre 2021 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, Novacyt présente les dernières informations concernant la commercialisation de ses tests COVID-19 au Royaume-Uni suite à la mise en oeuvre de la réglementation (amendement) sur les dispositifs médicaux (homologation des tests
Visit PageNews and Events
Validation of COVID-19 tests in the UK under CTDA legislation
Paris, France and Camberley, UK – 2 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the availability of its COVID-19 tests in the UK following implementation of the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”). http://novacyt.com/wp-content/uploads/2021/11/Novacyt-Validation-of-COVID-19-tests-in-the-UK-under-CTDA-FINAL-ENG.pdf
Visit PageR&D update
Including launch of two new tests to differentiate between COVID-19 and common winter viruses, and between COVID-19 variants Paris, France and Camberley, UK – 30 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&D update. http://novacyt.com/wp-content/uploads/2021/09/Novacyt-RD-update.pdf
Visit Page